• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Characterization molecular and immunologic features of CML stem cells for treatment-free remission.

Research Project

Project/Area Number 18K08375
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 54010:Hematology and medical oncology-related
Research InstitutionKindai University

Principal Investigator

MATSUMUTA Itaru  近畿大学, 医学部, 教授 (00294083)

Co-Investigator(Kenkyū-buntansha) 田中 宏和  近畿大学, 医学部, 准教授 (40360846)
頼 晋也  近畿大学, 医学部, 講師 (70460855)
森田 泰慶  近畿大学, 医学部, 講師 (80411594)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords慢性骨髄性白血病 / 分子標的 / 腫瘍免疫 / アミノ酸代謝 / CML / CML幹細胞 / チロシンキナーゼ阻害薬 / 免疫チェックポイント分子
Outline of Final Research Achievements

In this study, we analyzed immune evasion mechanisms of residual chronic myeloid leukemia stem cells (CML-LSCs) during the treatment with tyrosine kinase inhibitors (TKIs). Both expression of immune checkpoint molecule, PDL1 and activation of immunosuppressive enzyme, IDO1 were induced through the activation of CD120a/NF-κB signaling pathway in phenotypically defined CD34+38-120a+225+ cells, which we previously identified as CML-LSC. Furthermore, CML-LSCs suppressed cytotoxic T cell activity and induced a local recruitment of immunosuppressive populations such as regulatory T cells and myeloid-derived suppressor cells, leading to an immunosuppressive bone marrow milieu undergoing TKI therapy.

Academic Significance and Societal Importance of the Research Achievements

本研究は、CMLの免疫回避機構における腫瘍免疫とアミノ酸代謝との関連を明らかにしたものであり学術的意義は高い。本研究により、組織内IDO1活性を指標としたTKI の中止可能な症例の選別法だけでなく、治癒に向けたIDO1阻害によるCML-LSCに対する新規治療法を開発する上で、重要な知見が得られたと考えられる。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (41 results)

All 2021 2020 2019 2018 2017

All Journal Article (27 results) (of which Peer Reviewed: 27 results,  Open Access: 24 results) Presentation (14 results) (of which Int'l Joint Research: 4 results)

  • [Journal Article] Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.2021

    • Author(s)
      Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y
    • Journal Title

      Int J Hematol.

      Volume: 113 Issue: 3 Pages: 395-403

    • DOI

      10.1007/s12185-020-03032-3

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia2020

    • Author(s)
      Taniguchi Y, Takahashi N, Miura M, Hirase C, Sueda S, Espinoza JL, Rai S, Nakayama S, Serizawa K, Kumode T, Watatani Y, Morita Y, Tanaka H, Matsumura I.
    • Journal Title

      Internal Medicine

      Volume: 59 Issue: 21 Pages: 2745-2749

    • DOI

      10.2169/internalmedicine.4871-20

    • NAID

      130007934222

    • ISSN
      0918-2918, 1349-7235
    • Year and Date
      2020-11-01
    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature.2020

    • Author(s)
      Takeshita A, Asou N, Atsuta Y, Furumaki H, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Minamiguchi H, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y.
    • Journal Title

      Cancers (Basel)

      Volume: 12(6) Issue: 6 Pages: 1444-1444

    • DOI

      10.3390/cancers12061444

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line2020

    • Author(s)
      Sakurai M, Okamoto S, Matsumura I, Murakami S, Takizawa M, Waki M, Hirano D, Watanabe-Nakaseko R, Kobayashi N, Iino M, Mitsui H, Ishikawa Y, Takahashi N, Kawaguchi T, Suzuki R, Yamamoto K, Kizaki M, Ohnishi K, Naoe T, Akashi K; New TARGET investigators.
    • Journal Title

      Int J Hematol.

      Volume: 111 Issue: 6 Pages: 912-825

    • DOI

      10.1007/s12185-020-02843-8

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor2020

    • Author(s)
      Ono Takaaki、Takahashi Naoto、Kizaki Masahiro、Kawaguchi Tatsuya、Suzuki Ritsuro、Yamamoto Kazuhito、Ohnishi Kazunori、Naoe Tomoki、Matsumura Itaru
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 10 Pages: 3714-3725

    • DOI

      10.1111/cas.14580

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia2020

    • Author(s)
      Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, Sekiguchi N, Tanetsugu Y, Fukuhara K, Ohkura M, Koide Y, Takahashi N.
    • Journal Title

      International Journal of Hematology

      Volume: 112 Issue: 1 Pages: 24-32

    • DOI

      10.1007/s12185-020-02878-x

    • NAID

      120007036312

    • URL

      https://ocu-omu.repo.nii.ac.jp/records/2019911

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V.2020

    • Author(s)
      Shinya Rai, Hirokazu Tanaka*, Mai Suzuki, J. Luis Espinoza, Takahiro Kumode, Akira Tanimura, Yasuyoshi Morita, Yoichi Tatsumi, Takafumi Yokota, Kenji Oritani, Toshio Watanabe, Yuzuru Kanakura, and Itaru Matsumura.
    • Journal Title

      Nature Communications

      Volume: 11 Issue: 1 Pages: 4147-4147

    • DOI

      10.1038/s41467-020-17666-8

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.2019

    • Author(s)
      Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y
    • Journal Title

      Leukemia

      Volume: 33 Issue: 2 Pages: 358-370

    • DOI

      10.1038/s41375-018-0233-7

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Antidiuretic hormone‐ and interleukin‐6‐producing angioimmunoblastic T‐cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion2019

    • Author(s)
      Taniguchi Takahide、Nakayama Shoko、Morita Yasuyoshi、Rai Shinya、Espinoza Jorge L.、Matsumura Itaru
    • Journal Title

      British Journal of Haematology

      Volume: 184 Issue: 2 Pages: 121-121

    • DOI

      10.1111/bjh.15689

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality2019

    • Author(s)
      Rai Shinya、Espinoza J. Luis、Morita Yasuyoshi、Tanaka Hirokazu、Matsumura Itaru
    • Journal Title

      Frontiers in Immunology

      Volume: 9

    • DOI

      10.3389/fimmu.2018.03031

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells2019

    • Author(s)
      Tanaka Hirokazu、Espinoza J.、Fujiwara Ryosuke、Rai Shinya、Morita Yasuyoshi、Ashida Takashi、Kanakura Yuzuru、Matsumura Itaru
    • Journal Title

      Cells

      Volume: 8 Issue: 3 Pages: 226-226

    • DOI

      10.3390/cells8030226

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia2019

    • Author(s)
      Nakayama Shoko、Morita Yasuyoshi、Espinoza Jorge Luis、Rai Shinya、Oyama Yasuyo、Taniguchi Takahide、Miyake Yoshiaki、Tanaka Hirokazu、Matsumura Itaru
    • Journal Title

      Leukemia & Lymphoma

      Volume: 60 Issue: 2 Pages: 1-3

    • DOI

      10.1080/10428194.2019.1665665

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.2019

    • Author(s)
      Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators.
    • Journal Title

      Int J Hematol

      Volume: 109 Issue: 4 Pages: 426-439

    • DOI

      10.1007/s12185-019-02613-1

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).2019

    • Author(s)
      Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.
    • Journal Title

      Int J Hematol

      Volume: 110 Issue: 6 Pages: 675-682

    • DOI

      10.1007/s12185-019-02736-5

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab.2018

    • Author(s)
      Rai S, Tanaka H, Fujimoto K, Kumode T, Inoue H, Taniguchi Y, Morita Y, Espinoza JL, Tatsumi Y, Ashida T, Matsuoka R, Kikuti YY, Nakamura N, Matsumura I.
    • Journal Title

      Cancers (Basel).

      Volume: 10 Issue: 9 Pages: 304-304

    • DOI

      10.3390/cancers10090304

    • NAID

      120007133039

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry2018

    • Author(s)
      Nakaya A, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida SI, Uoshima N, Kawata E, Uchiyama H, Shimura Y, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, Shindo M, Tanaka H, Shimazaki C, Hino M, Kuroda J, Kanakura Y, Takaoari-Kondo A, Nomura S, Matsumura I
    • Journal Title

      Leukemia Research Reports

      Volume: 10 Pages: 7-10

    • DOI

      10.1016/j.lrr.2018.07.001

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial2018

    • Author(s)
      Morita Yasuyoshi、Maeda Yasuhiro、Yamaguchi Terufumi、Urase Fumiaki、Kawata Shuhei、Hanamoto Hitoshi、Tsubaki Kazuo、Ishikawa Jun、Shibayama Hirohiko、Matsumura Itaru、Matsuda Mitsuhiro
    • Journal Title

      Cancer Science

      Volume: 109 Issue: 10 Pages: 3209-3215

    • DOI

      10.1111/cas.13739

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Tumor necrosis factor- and interleukin-6-producing high-grade B-cell lymphoma, not otherwise specified in the pleura2018

    • Author(s)
      Nakayama Shoko、Matsuda Mitsuhiro、Adachi Tatsuya、Sueda Sanae、Ueda Kayo、Kawahara Kunimitsu、Ohashi Yuka、Awaji Sumie、Hashimoto Shigeo、Matsumura Itaru
    • Journal Title

      Leukemia Research Reports

      Volume: 10 Pages: 1-3

    • DOI

      10.1016/j.lrr.2018.06.001

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report2018

    • Author(s)
      Serizawa Kentaro、Tanaka Hirokazu、Morita Yasuyoshi、Taniguchi Takahide、Ashida Takashi、Matsumura Itaru
    • Journal Title

      Frontiers in Oncology

      Volume: 8 Pages: 204-204

    • DOI

      10.3389/fonc.2018.00204

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001–2005 using the Japan Adult Leukemia Study Group AML201 protocols2018

    • Author(s)
      Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y
    • Journal Title

      Support Care Cancer

      Volume: 26 Issue: 12 Pages: 4187

    • DOI

      10.1007/s00520-018-4292-0

    • URL

      https://localhost/en/publications/6c5d302c-5fe3-459c-8ecb-ce08638f873c

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Adult T cell leukemia/lymphoma with different pathological features in each tumor site2018

    • Author(s)
      Nakayama Shoko、Matsuda Mitsuhiro、Adachi Tatsuya、Sueda Sanae、Ohashi Yuka、Awaji Sumie、Hashimoto Shigeo、Matsumura Itaru
    • Journal Title

      Annals of Hematology

      Volume: 97 Issue: 6 Pages: 1095-1096

    • DOI

      10.1007/s00277-018-3272-2

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors2018

    • Author(s)
      松村 到
    • Journal Title

      Rinsho Ketsueki

      Volume: 59 Issue: 1 Pages: 13-26

    • DOI

      10.11406/rinketsu.59.13

    • NAID

      130006337957

    • ISSN
      0485-1439, 1882-0824
    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum2018

    • Author(s)
      Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; KMF
    • Journal Title

      International Journal of Hematology

      Volume: 107 Issue: 5 Pages: 541-550

    • DOI

      10.1007/s12185-018-2416-4

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial)2018

    • Author(s)
      Ishikawa Jun、Matsumura Itaru、Kawaguchi Tatsuya、Kuroda Junya、Nakamae Hirohisa、Miyamoto Toshihiro、Matsuoka Ken-ichi、Shibayama Hirohiko、Hino Masayuki、Hirase Chikara、Kamimura Tomohiko、Shimose Takayuki、Akashi Koichi、Kanakura Yuzuru
    • Journal Title

      International Journal of Hematology

      Volume: 107 Issue: 5 Pages: 535-540

    • DOI

      10.1007/s12185-018-2401-y

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study2018

    • Author(s)
      Harada Y、Nagata Y、Kihara R、Ishikawa Y、Asou N、Ohtake S、Miyawaki S、Sakura T、Ozawa Y、Usui N、Kanamori H、Ito Y、Imai K、Suehiro Y、Kobayashi S、Kitamura K、Sakaida E、Onizuka M、Takeshita A、Ishida F、Suzushima H、Ishizawa K、Naoe T、Matsumura I、Miyazaki Y、Ogawa S、Kiyoi H
    • Journal Title

      Leukemia Research

      Volume: 66 Pages: 20-27

    • DOI

      10.1016/j.leukres.2018.01.008

    • NAID

      120006473597

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial2017

    • Author(s)
      Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I,Matsuda A, Aoki M, Ito K, Shibayama H.
    • Journal Title

      Int J Hematol.

      Volume: 107 Issue: 3 Pages: 327-336

    • DOI

      10.1007/s12185-017-2353-7

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study2017

    • Author(s)
      Takahashi Naoto、Miyata Yasuhiko、Kobayashi Shinichi、Usuki Kensuke、Matsumura Itaru、Minami Yosuke、Usui Noriko、Fukuda Tetsuya、Kobayashi Yukio、Kiyoi Hitoshi、et al.
    • Journal Title

      Int J Hematol

      Volume: 107 Issue: 2 Pages: 185-193

    • DOI

      10.1007/s12185-017-2334-x

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML2122020

    • Author(s)
      Matsumura I, Ohtake S, Atsuta Y , et al.
    • Organizer
      62th ASH Annual Meeting and Exposition
    • Related Report
      2020 Annual Research Report
    • Int'l Joint Research
  • [Presentation] ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study2020

    • Author(s)
      Hanamoto H, Morita Y, Matsumura I, et al.
    • Organizer
      62th ASH Annual Meeting and Exposition
    • Related Report
      2020 Annual Research Report
    • Int'l Joint Research
  • [Presentation] CML治療の現状と今後2020

    • Author(s)
      松村 到
    • Organizer
      第82回日本血液学会学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] Infiltration of effector regulatory T cells is associated with poor prognosis in diffuse large B-cell lymphoma, not otherwise specified2019

    • Author(s)
      Nakayama S,Tanaka H, Luis Espinoza, Morita Y, Shinya Rai, Itaru Matsumura
    • Organizer
      The 10th JSH International Symposium 2019 in Ise-Shima
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] 慢性骨髄性白血病治療の進歩2019

    • Author(s)
      松村到
    • Organizer
      第57回日本癌治療学会学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] BCR-ABLINS35bpはCMLの長期予後に悪影響を与えない:新ターゲット観察研究12019

    • Author(s)
      山本 一仁, 高橋 直人, 湯田 淳一朗, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 大西 一功, 直江 知樹, 松村 到
    • Organizer
      第81回日本血液学会学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] 新TARGET観察研究1における高齢者慢性骨髄性白血病の予後解析2019

    • Author(s)
      小野 孝明, 高橋 直人, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 山本 一仁, 大西 一功, 直江 知樹, 松村 到
    • Organizer
      第81回日本血液学会学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] チャールソン併存疾患指数が慢性骨髄性白血病の予後に与える影響―新TARGET観察研究12019

    • Author(s)
      小野 孝明, 高橋 直人, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 山本 一仁, 大西 一功, 直江 知樹, 松村 到
    • Organizer
      第81回日本血液学会学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] 第2世代TKIは初診時付加的染色体異常を有するCMLの予後を改善し得る:新TARGET観察研究 12019

    • Author(s)
      吉岡 智子, 高橋 直人, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 山本 一仁, 大西 一功, 直江 知樹, 松村 到
    • Organizer
      第81回日本血液学会学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] In vitro safety and efficacy of S888711, a novel thrombopoietin receptor agonist, in Myelodysplastic syndrome2018

    • Author(s)
      Keigo Sano, Hirokazu Tanaka, Itaru Matsumura
    • Organizer
      第1回国際がん研究シンポジウム
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] 症候性骨髄腫1414例の後方視的解析:関西骨髄腫フォーラムからの最新報告2018

    • Author(s)
      田中 宏和, 芹澤 憲太郎, 中谷 綾, 金子 仁臣, 太田 健介, 小杉 智, 八木 秀男, 花本 仁, 淵田 真一, 志村 勇司, 柴山 浩彦, 小原 尚恵, 中谷 英仁, 諫田 淳也, 魚嶋 伸彦, 和田 勝也, 烏野 隆博, 松井 利充, 内山 人二, 松田 光弘, 足立 陽子, 高折 晃史, 黒田 純也, 谷脇 雅史, 島崎 千尋, 日野 雅之, 今田 和典, 野村 昌作, 金倉 譲, 松村 到
    • Organizer
      第80回日本血液学会学術集会
    • Related Report
      2018 Research-status Report
  • [Presentation] 造血器腫瘍における治療標的としてのチロシンキナーゼ2018

    • Author(s)
      松村 到
    • Organizer
      第80回日本血液学会学術集会
    • Related Report
      2018 Research-status Report
  • [Presentation] CD34陽性ヒト骨髄腫幹細胞の同定と特性解析2018

    • Author(s)
      芹澤 憲太郎, 田中 宏和, 福井 彩乃, 藤原 亮介, 佐野 圭吾, 口分田 貴裕, 谷口 康博, 森田 泰慶, ルイス エスピノザ, 辰巳 陽一, 芦田 隆司, 松村 到
    • Organizer
      第80回日本血液学会学術集会
    • Related Report
      2018 Research-status Report
  • [Presentation] 異常なRTKの細胞内輸送阻害は急性骨髄性白血病における有望な治療標的である。2018

    • Author(s)
      頼 晋也 田中 宏和, 鈴木 麻衣, Luis Espinoza, 谷村 朗, 森田 泰慶, 辰巳 陽一, 横田 貴史, 織谷 健司, 渡邊 俊雄, 金倉 譲, 松村 到
    • Organizer
      第80回日本血液学会学術集会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi